Clinical trials
High Risk clinical trials
Below are recruiting high risk clinical trials, each written for real people, not researchers. We’re tracking 923 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07349069RecruitingPhase 3
HRS-8080 vs. standard hormone therapy for early breast cancer
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
Nanjing, JiangsuAges 18–75 - NCT07352111Recruiting
Heart risk in those with family history of heart attack
This study looks at people who have a family history of heart disease but no known heart problems or symptoms. It aims to understand if hidden plaque buildup in the arteries may be present.
MilanAges 40–70 - NCT07359768Recruiting
Testing a noninvasive device for heart disease risk
This trial uses a noninvasive device to examine small blood vessels in people at high risk for heart disease. It may help doctors better understand who needs preventive care.
Stockholm, DanderydAges Any age - NCT07361679RecruitingPhase 4
Aspirin plus heparin vs aspirin alone for preeclampsia prevention
This trial tests whether adding a daily blood-thinning injection (heparin) to low-dose aspirin helps prevent preeclampsia better than aspirin alone for pregnant women at high risk.
Athens, AtticaAges 18 years+ - NCT07370246Recruiting
Carotid stenting for high-risk carotid surgery patients
This trial tests whether placing a stent in the narrowed carotid artery is a good option for people who are at high risk for the standard surgery (carotid endarterectomy). If you have significant blockages in your neck arteries and certain health or anatomical factors that make surgery riskier, this study may be for you.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07375563RecruitingPhase 3
Chemoimmunotherapy with NK cells for high-risk neuroblastoma
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
MoscowAges 1.5 years–18 years - NCT07389616RecruitingPhase 2/Phase 3
Preventing lymphoma return after transplant
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07395596RecruitingPhase 4
Remimazolam for Bronchoscopy in High-Risk Patients
This trial tests a sedative called remimazolam for people who are at higher risk during a painless bronchoscopy (a lung exam). It aims to see if this drug is safe and effective for you.
Hangzhou, ZhejiangAges 18 years+ - NCT00040352Recruiting
Understanding melanoma risk in families and individuals
This research study helps doctors understand why some people and families develop melanoma (a serious skin cancer), especially in unusual circumstances. Researchers will collect medical histories, examine skin, and may do genetic testing to identify risk factors that could help with earlier detection and prevention.
Bethesda, MarylandAges 4 weeks–99 years - NCT01804634RecruitingPhase 2
Reduced-intensity stem cell transplant for high-risk solid tumors
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
Baltimore, MarylandAges 1–50 - NCT00898313Recruiting
Study looks for cancer clues in people at high risk for lung cancer
This study enrolls adults who are being checked for possible lung cancer because of concerning symptoms or a high-risk situation. It aims to find molecular (cell/DNA-related) predictors that may help doctors better recognize lung cancer earlier.
Nashville, TennesseeAges 18 years+ - NCT00009633Recruiting
Follow-up care for very premature infants born at specialized hospitals
This study follows babies born very early (before 27 weeks of pregnancy) who were treated at specialized neonatal centers. Researchers track their health and development over time to better understand how to care for extremely premature infants.
Birmingham, AlabamaAges 1.5 years–2.2 years - NCT01898039RecruitingPhase 1/Phase 2
Vaccine study for certain melanoma patients with specific blood markers
This trial tests a modified vaccine to help the immune system recognize melanoma. It is mainly for people with melanoma at higher risk or certain stages, and who have specific inherited tissue markers on blood testing.
JerusalemAges Any age - NCT01515527RecruitingPhase 2
Cladribine plus low-dose cytarabine and decitabine for AML or MDS
This Phase 2 study tests a combination chemotherapy plan (cladribine, low-dose cytarabine, and decitabine) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to shrink the leukemia/MDS and improve outcomes, including for certain people who may not tolerate standard treatment.
Houston, TexasAges 60 years+ - NCT01704716RecruitingPhase 3
Study for high-risk neuroblastoma in children and teens
This Phase 3 trial tests treatments for children and teens with high-risk neuroblastoma, aiming to improve outcomes by using biology-based risk information. It also requires limited prior chemotherapy and specific timing after diagnosis.
AdelaideAges 1 month–21 years - NCT02115295RecruitingPhase 2
Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Houston, TexasAges 18–65 - NCT02605421RecruitingPhase 2
High-risk neuroblastoma stem cell treatment after initial response
This Phase 2 study tests intensive treatment (high-dose “consolidation”) followed by rescue with your own stem cells for high-risk neuroblastoma. It may help patients keep the cancer from coming back after it has improved or stabilized from initial chemotherapy.
Minneapolis, MinnesotaAges Up to 30 years - NCT02775461Recruiting
Registry for people at high risk for pancreatic cancer
This study is a registry (a way to track health over time) for people with a strong family history or certain inherited genetic risks for pancreatic cancer. It may help doctors learn how best to monitor and protect high-risk people, and to see who benefits most from follow-up.
New York, New YorkAges 18 years+ - NCT03260842Recruiting
Biobank study for people at high risk of pancreatic cancer
This study collects and stores samples (bio-specimens) from adults who have pancreas cysts and are at higher risk for pancreatic cancer. The goal is to help researchers improve early detection so future patients may be diagnosed sooner.
Stanford, CaliforniaAges 18 years+ - NCT06246149RecruitingPhase 3
Tebentafusp after treatment for high-risk eye melanoma
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
Lake Success, New YorkAges 18 years+ - NCT07527689Recruiting
Faster vs. Standard Radiation After Breast Cancer Surgery
This study compares two radiation schedules for breast cancer patients at high risk of cancer returning in lymph nodes. Both use modern radiation therapy, but one delivers treatment faster (ultra-hypofractionated) while the other uses a more moderate schedule. The goal is to see which approach works better with fewer side effects.
ShanghaiAges 18 years+ - NCT00870129Recruiting
MRI mapping to plan radiation for certain brain tumors
This study uses MRI scans to find higher-risk areas in certain brain and other solid tumors and help plan radiation treatment. It also looks for changes in tumor “metabolites” (chemicals in the tumor) that may relate to how the tumor behaves.
New York, New YorkAges 18 years+ - NCT07417397RecruitingPhase 3
TACE after surgery for high-risk liver cancer
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
NanningAges 18–70 - NCT07418125Recruiting
Study of tumor cell clusters in high-risk early breast cancer
This trial looks at whether clusters of tumor cells in the blood can give more information about high-risk early breast cancer. It is for people with certain types of breast cancer who are about to start treatment before surgery (neoadjuvant therapy).
LjubljanaAges 18 years+
Hear when a new High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk?
- Yes. Clin2 currently lists 923 recruiting high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.